Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Myriad Genetics Inc. (MYGN:NASDAQ), powered by AI.
Myriad Genetics Inc. is currently trading at $4.25. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Myriad Genetics Inc. on Alpha Lenz.
Myriad Genetics Inc.'s P/E ratio is -1.1.
“Myriad Genetics Inc. trades at a P/E of -1.1 (undervalued) with modest ROE of -68.5%.”
Ask for details →Myriad Genetics Inc. is a biotechnology company specializing in the development and commercialization of genetic tests that assess risk for cancer and other hereditary conditions. The company is renowned for its pioneering efforts in molecular diagnostics, offering tests that help individuals and healthcare providers make informed decisions about disease prevention and treatment. Myriad Genetics plays a critical role in the healthcare and medical research sectors by advancing personalized medicine and facilitating the understanding of genetic contributions to disease. Their testing portfolio includes products that identify genetic markers, providing insights into the likelihood of developing various cancers, such as breast and ovarian cancer, among other conditions. Myriad’s work supports oncologists, genetic counselors, and researchers by delivering highly reliable genetic insights crucial for patient care planning. Headquartered in Salt Lake City, Utah, Myriad Genetics continues to be at the forefront of genetic testing—driving innovation that enhances predictive medicine and impacts clinical decision-making.
“Myriad Genetics Inc. trades at a P/E of -1.1 (undervalued) with modest ROE of -68.5%.”
Ask for details →Myriad Genetics Inc. (ticker: MYGN) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 2,700 employees. Market cap is $394M.
The current price is $4.25 with a P/E ratio of -1.08x and P/B of 1.07x.
ROE is -68.45% and operating margin is -8.22%. Annual revenue is $825M.